May 4, 2018 - for progression in localized prostate cancer, it is not necessarily of .... therapy (antiandrogen withdrawal [AW] and alternative nonsteroidal.
[Downloaded free from http://www.ajandrology.com on Friday, May 4, 2018, IP: 128.240.225.118] Asian Journal of Andrology (2018) 20, 1–6 www.asiaandro.com; www.ajandrology.com
Open Access
Prostate Cancer
ORIGINAL ARTICLE
Treatment strategy for metastatic prostate cancer with extremely high PSA level: reconsidering the value of vintage therapy Yasutaka Yamada1,2, Shinichi Sakamoto2, Yoshiyasu Amiya1, Makoto Sasaki1, Takayuki Shima1, Akira Komiya2, Noriyuki Suzuki1, Koichiro Akakura3, Tomohiko Ichikawa2, Hiroomi Nakatsu1 The prognostic significance of initial prostate‑specific antigen (PSA) level for metastatic prostate cancer remains uncertain. We investigated the differences in prognosis and response to hormonal therapies of metastatic prostate cancer patients according to initial PSA levels. We analyzed 184 patients diagnosed with metastatic prostate cancer and divided them into three PSA level groups as follows: low (0.24)a
1.05
0.60–1.87
0.961
NA
NA
NA
T stage ≥T3b
0.85
0.49–1.57
0.594
NA
NA
NA
EOD ≥3
1.24
0.76–1.98
0.391
NA
NA
NA
1
0.62–1.64
0.997
NA
NA
NA
High‑volume prostate cancer Nadir PSA of initial ADT (13 g dl−1)b
